RVL Pharmaceuticals plc – Plans of Reorganization, Merger, Acquisition or Similar Watch

from 8-K 143 pages Plan of reorganization, merger, acquisition or similar

from 8-K 104 pages Purchase and Sale Agreement by and Among the Sellers Listed Herein, Osmotica Pharmaceuticals Plc, Acella Holdings, LLC, and Alora Pharmaceuticals, LLC Dated as of June 24, 2021

from SC 13D 56 pages Shareholders Agreement Dated as of October 17, 2018 Among Osmotica Pharmaceuticals PLC Acp Holdco (Offshore), L.P. Acp III Aiv, L.P. Altchem Limited Orbit Co-Invest A-I LLC Orbit Co-Invest 1 LLC Orbit Co-Invest II LLC Orbit Co-Invest III LLC and the Management Shareholders Identified Herein

from S-1 40 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission. Stock Purchase Agreement by and Among the Shareholders of Revitalid, Inc. (“Company”) and Osmotica Pharmaceutical Corp. (“Buyer”) Dated as of October 24, 2017 This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission

from S-1 135 pages Business Combination Agreement Among the Osmotica Shareholders, as Defined Herein, Osmotica Holdings Corp Limited, Altchem Limited, as the Osmotica Shareholders’ Representative, the Vertical/Trigen Shareholders, as Defined Herein, Vertical/Trigen Holdings, LLC, Avista Capital Partners III GP, LP, as the Vertical/Trigen Shareholders’ Representative, and Osmotica Holdings S.C.SP. Dated as of December 3, 2015

from DRS/A 40 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission. Stock Purchase Agreement by and Among the Shareholders of Revitalid, Inc. (“Company”) and Osmotica Pharmaceutical Corp. (“Buyer”) Dated as of October 24, 2017 This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission

from DRS/A 40 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission. Stock Purchase Agreement by and Among the Shareholders of Revitalid, Inc. (“Company”) and Osmotica Pharmaceutical Corp. (“Buyer”) Dated as of October 24, 2017 This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission

from DRS 40 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission. Stock Purchase Agreement by and Among the Shareholders of Revitalid, Inc. (“Company”) and Osmotica Pharmaceutical Corp. (“Buyer”) Dated as of October 24, 2017 This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [***] and Has Been Filed Separately With the Securities and Exchange Commission

from DRS 135 pages Business Combination Agreement Among the Osmotica Shareholders, as Defined Herein, Osmotica Holdings Corp Limited, Altchem Limited, as the Osmotica Shareholders’ Representative, the Vertical/Trigen Shareholders, as Defined Herein, Vertical/Trigen Holdings, LLC, Avista Capital Partners III GP, LP, as the Vertical/Trigen Shareholders’ Representative, and Osmotica Holdings S.C.SP. Dated as of December 3, 2015